Mechanisms of target organ damage caused by hypertension: Therapeutic potential

被引:122
作者
Cohuet, G. [1 ]
Struijker-Boudier, H. [1 ]
机构
[1] Cardiovasc Res Inst Maastricht, Maastricht, Netherlands
关键词
hypertension; target organ damage; microcirculation; therapy ronasdsd;
D O I
10.1016/j.pharmthera.2005.09.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hypertension is a major risk factor for cardiovascular mortality and morbidity through its effects on target organs like the brain, heart, and kidney. Structural alterations in the microcirculation form a major link between hypertension and target organ damage. In this review, we describe damages related to hypertension in these target organs and the mechanisms involved in the pathogenesis of hypertension-induced cardiovascular diseases such as dementia, cardiac ischemia and remodeling, or nephropathy. We also focus on the therapeutical potential on the basis of such mechanisms. Several antihypertensive agents like diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin II (Ang II) receptor antagonists, beta-blockers, or calcium channel blockers (CCBs) have been shown to reduce effectively hypertension associated cardiovascular events and to improve end organ damage. More recently, aldosterone antagonism has also shown beneficial effects. Part of the favorable effects of these agents is due to blood pressure lowering as such. Other mechanisms such as oxidative stress, inflammation, or endothelial dysfunction have appeared to play a key role in the pathogenesis of target organ damage and therefore represent another important pathway for therapy. In this review, we discuss the different therapeutic approaches aiming at reducing cardiovascular events and damages induced by hypertension. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:81 / 98
页数:18
相关论文
共 240 条
[71]  
Frishman William H, 2002, Heart Dis, V4, P380, DOI 10.1097/00132580-200211000-00007
[72]  
Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967
[73]   Mechanisms of disease: Acute-phase proteins and other systemic responses to inflammation [J].
Gabay, C ;
Kushner, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (06) :448-454
[74]   Testing the validity of the lacunar hypothesis: The northern Manhattan stroke study experience [J].
Gan, R ;
Sacco, RL ;
Kargman, DE ;
Roberts, JK ;
BodenAlbala, B ;
Gu, Q .
NEUROLOGY, 1997, 48 (05) :1204-1211
[75]  
GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450
[76]   Enhanced platelet release of superoxide anion in systemic hypertension:: role of AT1 receptors [J].
Germanò, G ;
Sanguigni, V ;
Pignatelli, P ;
Caccese, D ;
Lenti, L ;
Ragazzo, M ;
Lauro, R ;
Violi, F .
JOURNAL OF HYPERTENSION, 2004, 22 (06) :1151-1156
[77]  
Goldblatt H, 1934, J EXP MED, V59, P347, DOI 10.1084/jem.59.3.347
[78]   Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass? [J].
Gosse, P ;
Jullien, V ;
Jarnier, P ;
Lemetayer, P ;
Clementy, J .
JOURNAL OF HUMAN HYPERTENSION, 1999, 13 (08) :505-509
[79]   A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL STUDY OF VARIOUS DOSES OF LOSARTAN POTASSIUM COMPARED WITH ENALAPRIL MALEATE IN PATIENTS WITH ESSENTIAL-HYPERTENSION [J].
GRADMAN, AH ;
ARCURI, KE ;
GOLDBERG, AI ;
IKEDA, LS ;
NELSON, EB ;
SNAVELY, DB ;
SWEET, CS .
HYPERTENSION, 1995, 25 (06) :1345-1350